<div class="data-content">
  
  <div class="mxb-6 plr-1 ptb-0-2 head-content large"><b>Comparison of Anticoagulants Table</b></div>
  <div class="table-body plr-1">
    <div class="table-wrapper">
      <div id="tableHeaders" class="tableHeaders">
        <table>
          <thead>
            <tr>
              <th class="head-bold" style="width: 120px;">&nbsp;</th>
              <th class="head-bold" style="width: 160px;">Unfractionated Heparin</th>
              <th class="head-bold" style="width: 160px;">Argatroban</th>
              <th class="head-bold" style="width: 160px;">Bivalirudin</th>
            </tr>
          </thead>
        </table>
      </div>
      <div id="tableBody" class="tableBody" onscroll="{ document.getElementById('tableHeaders').scrollLeft = this.scrollLeft;}">
        <table>
          <thead style="line-height:0px; opacity:0">
            <tr>
              <th>&nbsp;</th>
              <th>&nbsp;</th>
              <th>&nbsp;</th>
              <th>&nbsp;</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td class="head-bold">Mechanism of Action</td>
              <td>Antithrombin-dependent Factor X and Factor II inhibition</td>
              <td>Reversible direct Factor II inhibition</td>
              <td>Reversible direct Factor II inhibition </td>
            </tr>
            <tr>
              <td class="head-bold">Metabolism</td>
              <td>Hepatic</td>
              <td>Hepatic</td>
              <td>
                <p>80% proteolytic enzymes</p>
                <p>20% renal</p>
              </td>
            </tr>
            <tr>
              <td class="head-bold">Half Life (min)</td>
              <td>
                <p>60–90 (adults)</p>
                <p>35–75 (pediatrics)</p>
              </td>
              <td>
                <p>39-51</p>
                <p>May be altered with impaired hepatic function or critically-ill patients with multi-organ failure</p>
              </td>
              <td>
                <p>25 (adults)</p>
                <p>15–42 (pediatrics)</p>
                <p>May be altered with impaired renal function</p>
              </td>
            </tr>
            <tr>
              <td class="head-bold">Monitoring</td>
              <td>
                <ul class="pl-1">
                  <li>AntiXa</li>
                  <li>aPTT</li>
                  <li>Viscoelastic tests</li>
                </ul>
              </td>
              <td>
                <ul class="pl-1">
                  <li>aPTT</li>
                  <li>Diluted thrombin time</li>
                  <li>Ecarin chromogenic assay</li>
                </ul>
              </td>
              <td>
                <ul class="pl-1">
                  <li>aPTT</li>
                  <li>Diluted thrombin time</li>
                  <li>Ecarin chromogenic assay</li>
                </ul>
              </td>
            </tr>
            <tr>
              <td class="head-bold">Antidote</td>
              <td>Protamine</td>
              <td>No specific antidote, consider PCC</td>
              <td>No specific antidote, consider PCC and renal replacement therapy</td>
            </tr>
            <tr>
              <td class="head-bold" style="vertical-align: top!important;">
                <div>Monitoring pitfalls [LINK]</div>
              </td>
              <td>
                <div class=""><b>AntiXa:</b></div>
                <ul class="pl-1">
                  <li>Reagent specific differences (content of dextran sulfate and AT III)</li>
                  <li>Assay specific differences (clot-based or chromogenic detection)</li>
                </ul>
                <div class=""><b>aPTT:</b></div>
                <ul class="pl-1">
                  <li>Consider shortening (increased FVIII activity) and prolonging (decreased FXII activity, lupus anticoagulant) confounders.</li>
                </ul>
              </td>
              <td>
                <div class=""><b>aPTT:</b></div>
                <ul class="pl-1">
                  <li>Consider shortening (increased FVIII activity) and prolonging (decreased FXII activity, lupus anticoagulant) confounders</li>
                </ul>
                <div class=""><b>Diluted thrombin time (hemoclot assay):</b></div>
                <ul class="pl-1">
                  <li>Limited data on appropriate target range.</li>
                </ul>
                <div class=""><b>Ecarin chromogenic assay:</b></div>
                <ul class="pl-1">
                  <li>Limited data on appropriate target range.</li>
                </ul>
              </td>
              <td>
                <div class=""><b>aPTT:</b></div>
                <ul class="pl-1">
                  <li>Consider shortening (increased FVIII activity) and prolonging (decreased FXII activity, lupus anticoagulant) confounders</li>
                </ul>
                <div class=""><b>Diluted thrombin time (hemoclot assay):</b></div>
                <ul class="pl-1">
                  <li>Limited data on appropriate target range.</li>
                </ul>
                <div class=""><b>Ecarin chromogenic assay:</b></div>
                <ul class="pl-1">
                  <li>Limited data on appropriate target range.</li>
                </ul>
              </td>
            </tr>
          </tbody>
        </table>
      </div>

    </div>
  </div>
</div>